{"entity":{"id":"netris-pharma","kind":"company","name":"Netris Pharma","aka":["NETRIS Pharma SAS"],"tldr":"Netris Pharma is a Lyon biotech built on Patrick Mehlen's discovery that tumours use the guidance protein netrin-1 to survive; its antibody NP137 blocks netrin-1 and has shown activity in endometrial cancer.","summary":"Netris Pharma develops therapies that restore the cell death normally triggered by dependence receptors when their ligand is absent. NP137 is a humanised antibody that neutralises netrin-1, a ligand many tumours over-produce to block this apoptosis. In a phase 1 study it was safe and produced responses in endometrial carcinoma, and a Nature paper in 2023 showed it reverses epithelial-to-mesenchymal transition and sensitises tumours to chemotherapy. It is being tested with carboplatin and paclitaxel, and with pembrolizumab, in endometrial and cervical cancers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.netrispharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["np137"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.netrispharma.com/","founded":2008,"investors":[],"funding":[]},"route":"/companies/netris-pharma/","neighbours":{"drug":[{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/"}]}}